“Three-Dimensional Breast Cancer Spheroids” submitted by radiotherapeutics researcher Debjani Pal is stunning. Brilliant blue dots pop from an electric sphere threaded with bright colors: greens, aqua, hot pink and red.
In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
ORNL hosted its fourth Artificial Intelligence for Robust Engineering and Science, or AIRES, workshop from April 18-20. Over 100 attendees from government, academia and industry convened to identify research challenges and investment areas, carving the future of the discipline.
Researchers at the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2022 R&D 100 Awards, plus special recognition for a battery-related green technology product.
Radioactive isotopes power some of NASA’s best-known spacecraft. But predicting how radiation emitted from these isotopes might affect nearby materials is tricky
Two staff members at the Department of Energy’s Oak Ridge National Laboratory have received prestigious HENAAC and Luminary Awards from Great Minds in STEM, a nonprofit organization that focuses on promoting STEM careers in underserved
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.